Immunic holder abrdn reports 6.05% ownership stake

Aberdeen Group plc and its subsidiary abrdn Inc. report beneficial ownership of 824,393 shares of Immunic, Inc. common stock, representing 6.05 % of the outstanding class.

Rhea-AI Filing Summary

Aberdeen Group plc and its subsidiary abrdn Inc. report beneficial ownership of 824,393 shares of Immunic, Inc. common stock, representing 6.05 % of the outstanding class. All of these shares are reported with shared, not sole, voting and dispositive power.

The ownership is held by abrdn Inc. on behalf of underlying clients, with Aberdeen Group plc identified as the parent and abrdn Holdings Limited as an intermediate holding company. This amendment updates Immunic’s CUSIP 4525EP200 following a stock split that was effective on April 27, 2026.

Key Figures

Beneficial ownership: 824,393 shares Percent of class: 6.05 % Shared voting power: 824,393 shares +3 more

6 metrics

Beneficial ownership 824,393 shares Amount of Immunic common stock beneficially owned by Aberdeen Group plc and abrdn Inc.

Percent of class 6.05 % Portion of Immunic’s outstanding common stock represented by the reported holdings

Shared voting power 824,393 shares Shares over which each reporting person has shared power to vote or direct the vote

Shared dispositive power 824,393 shares Shares over which each reporting person has shared power to dispose or direct disposition

Stock split effective date April 27, 2026 Date of stock split that led to updating Immunic’s CUSIP in this amendment

CUSIP 4525EP200 CUSIP number for Immunic, Inc. common stock following the April 27, 2026 stock split

Key Terms

beneficially owns, Shared Voting Power, dispositive power, parent holding company

4 terms

beneficially owns regulatory

"abrdn Inc. beneficially owns on behalf of our underlying clients..."

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Shared Voting Power regulatory

"5 | Sole Voting Power 0.00 6 | Shared Voting Power 824,393.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power regulatory

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 824,393.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

parent holding company regulatory

"Aberdeen Group plc is the parent company. abrdn Holdings Limited..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in Immunic (IMUX) do Aberdeen Group plc and abrdn Inc. report?

Aberdeen Group plc and abrdn Inc. report beneficial ownership of 824,393 shares of Immunic common stock, equal to 6.05 % of the class, with all shares subject to shared voting and shared dispositive power rather than sole control.

Who are the reporting entities in this Immunic (IMUX) Schedule 13G/A and where are they based?

The reporting entities are Aberdeen Group plc, based in Edinburgh, United Kingdom, and its subsidiary abrdn Inc., based in Philadelphia, Pennsylvania. Aberdeen Group plc is identified as the parent, with abrdn Holdings Limited as an intermediate holding company.

Do Aberdeen Group plc and abrdn Inc. have sole or shared voting power over Immunic (IMUX) shares?

They report 0 shares with sole voting power and 824,393 shares with shared voting power. The same figures apply to dispositive power: no sole dispositive power and shared dispositive power over 824,393 shares of Immunic common stock.

Why was this Immunic (IMUX) Schedule 13G/A amendment filed?

The amendment states it is being filed to update the issuer's CUSIP after a stock split effective April 27, 2026. The new CUSIP for Immunic’s common stock is listed as 4525EP200 in connection with this update.

Are the Immunic (IMUX) shares held directly by abrdn Inc. or on behalf of clients?

abrdn Inc. states that it beneficially owns the reported Immunic shares on behalf of underlying clients, indicating the position represents client accounts rather than proprietary holdings of the abrdn corporate entities themselves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 06:15 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

IMMUNIC, INC.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

4525EP200

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 4525EP200

1

Names of Reporting Persons

Aberdeen Group plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 824,393.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 824,393.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

824,393.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.05 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 4525EP200

1

Names of Reporting Persons

abrdn Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 824,393.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 824,393.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

824,393.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.05 %

12

Type of Reporting Person (See Instructions)

CO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IMMUNIC, INC.
(b)	Address of issuer's principal executive offices: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK, NEW YORK 10036
Item 2.
(a)	Name of person filing: Aberdeen Group plc abrdn Inc.
(b)	Address or principal business office or, if none, residence: Aberdeen Group plc: 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn Inc. 1900 Market Street Suite 200. Philadelphia, PA 19103
(c)	Citizenship: Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
(d)	Title of class of securities: Common Stock, par value $0.0001
(e)	CUSIP No.: 4525EP200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 824,393
(b)	Percent of class: 6.05 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aberdeen Group plc - 0 abrdn Inc. - 0
	(ii) Shared power to vote or to direct the vote: Aberdeen Group plc - 824,393 abrdn Inc. - 824,393
	(iii) Sole power to dispose or to direct the disposition of: Aberdeen Group plc - 0 abrdn Inc. - 0
	(iv) Shared power to dispose or to direct the disposition of: Aberdeen Group plc - 824,393 abrdn Inc. - 824,393
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aberdeen Group plc

Signature:	J. Clarke
Name/Title:	Jenny Clarke, Major Shareholding Reporting Analyst
Date:	07/10/2026

abrdn Inc.

Signature:	J. Clarke
Name/Title:	Jenny Clarke, Major Shareholding Reporting Analyst
Date:	07/10/2026

Exhibit Information

Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. This amendment is being filed to update the issuer's CUSIP following the stock split effective April 27, 2026.